Evidence map›Paper›PMID 31335357›Full record

ArticleClinical and translational gastroenterology2019

Primer on Precision Medicine for Complex Chronic Disorders.

David C Whitcomb

Registry-linked trialAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04306939 (Genomic Resources for Enhancing Available Therapies), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04306939 suspendednot on this map

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

TypeobservationalSponsorUniversity of PittsburghRan2014 to 2026Enrolled120,000ConditionsChronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic SteatohepatitisArmsvenipuncture, Questionnaires, Additional Sample Collections
3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. The personalized medicine discourse: archaeology and genealogy.Medicine, health care, and philosophy · 2021
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Precision medicine for pancreatic diseases.Current opinion in gastroenterology · 2020
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David C WhitcombDepartment of Medicine, Cell Biology and Molecular Physiology, and Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine promises patients with complex disorders the right treatment for the right patient at the right dose at the right time with expectation of better health at a lower cost. The demand for precision medicine highlights the limitations of modern Western medicine. Modern Western medicine is a population-based, top-down approach that uses pathology to define disease. Precision medicine is a bottom-up approach that identifies predisease disorders using genetics, biomarkers, and modeling to prevent disease. This primer demonstrates the contrasting strengths and limitations of each paradigm and why precision medicine will eventually deliver on the promises.

Indexed as

BiomarkersChronic DiseaseEvidence-Based MedicineGeneticsHumansImplementation ScienceModels, TheoreticalPrecision MedicineBiomarkers

Identifiers

PMID31335357
PMCPMC6708660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.